MetLife vs Reinsurance Group of America
MET and RGA side by side, both in life insurance. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MET and RGA compare
MetLife is the larger company, worth 3.7 times as much as Reinsurance Group of America ($63.6B against $17.3B).
On earnings, Reinsurance Group of America is cheaper: it trades at 11.6× trailing earnings, against 19.2× for MetLife.
Reinsurance Group of America grew revenue faster over the last twelve months (19.4% versus 8.7% for MetLife).
Reinsurance Group of America keeps more of each dollar of sales as profit, with a net margin of 5.8% compared with 4.6% at MetLife.
Both pay dividends: MetLife yields 2.3% and Reinsurance Group of America 1.4%.
Reinsurance Group of America scores higher on the StockData Score (10 against 7 for MetLife), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MET | RGA |
|---|---|---|
| Size and price | ||
| Market cap | $63.6B | $17.3B |
| Share price | $100.02 | $264.73 |
| Change, 1 year | 27.7% | 39.6% |
| Change, 5 years | 56.3% | 139% |
| Beta (5Y) | 0.87 | 0.59 |
| Employees | 46K | 4,300 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 4 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 2 (better) | 0 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 19.2× | 11.6× (better) |
| P/S | 0.8× | 0.7× (better) |
| P/B | 2.3× | 1.3× (better) |
| EV/EBITDA | 5.6× | – |
| PEG | – | 0.36 |
| Fair value | $61.83 | $262.09 |
| Margin of safety | −61.8% | −1.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.7% | 19.4% (better) |
| Revenue growth, 5Y average | 2.6% | 10.2% (better) |
| Net income growth (TTM) | −15.4% | 95.8% (better) |
| EPS growth (TTM) | −11.5% | 97.7% (better) |
| EPS growth, 5Y average | −3.7% | 22.9% (better) |
| Profitability | ||
| Operating margin | 8.3% | – |
| Net margin | 4.6% | 5.8% (better) |
| Return on equity | 13.2% (better) | 11.7% |
| Return on invested capital | 843% | – |
| Financial health | ||
| Debt / equity | 0.02 | – |
| Net debt / EBITDA | −4.09 | – |
| Altman Z-score | 0.27 | 0.31 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 2.3% (better) | 1.4% |
| Payout ratio | 41.6% | 16.2% |
| Years of dividend growth | 13 (better) | 4 |
| Dividend growth, 5Y average | 4.3% | 4.9% (better) |
| Buyback yield | 3.8% (better) | 1.6% |
| Shareholder yield | 6.2% (better) | 3.1% |
| Ownership | ||
| Held by institutions | 76.5% | 99.4% |
| Held by insiders | 16.4% | 0.30% |
| Insider net buying, 12 months | −$1.7M (better) | −$3.7M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 2.1% | – |
Go deeper
- MET stock overview
- MET income statement
- MET valuation and score
- RGA stock overview
- RGA income statement
- RGA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.